Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01453452
Other study ID # S1008
Secondary ID S1008U10CA037429
Status Completed
Phase N/A
First received
Last updated
Start date March 2012
Est. completion date January 2017

Study information

Verified date January 2020
Source Southwest Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Physical activity, diet, and counseling may help breast and colorectal cancer survivors to lose weight and improve their quality of life.

PURPOSE: This phase II trial studies how well exercise, diet, and counseling work in improving physical activity and weight loss in overweight women who are breast and colorectal cancer survivors.


Description:

OBJECTIVES:

Primary

- To determine the feasibility of a 12-month community-based combined physical activity and dietary change weight-loss intervention in overweight and sedentary female breast and colorectal cancer survivors recruited via the Southwest Oncology Group (SWOG).

- To estimate the effect size of the intervention on weight loss at 12 months.

Secondary

- To measure changes in anthropometric measures from baseline (body mass index [BMI], waist and hip circumference) at 6 and 12 months and body composition (% body fat as assessed by dual-energy X-ray absorptiometry [DXA] scan) at 12 months.

- To measure changes in minutes spent per week in moderate-to-vigorous aerobic activity from baseline using Curves attendance records and a 7-day physical activity assessment at 6 and 12 months.

- To measure changes from baseline to 6 and 12 months in dietary intake of carotenoids via serum carotenoid measures.

- To assess changes from baseline to 6 and 12 months in perceived benefit of dietary change, physical activity, and weight loss after a cancer diagnosis.

- To measure changes from baseline in metabolic and hormonal biomarkers associated with breast and colorectal cancer recurrence risk (fasting insulin, fasting glucose, hemoglobin A1C, bioavailable estradiol, free testosterone, and adiponectin) at 6 and 12 months.

- To assess changes from baseline in anxiety, depression, fatigue, sleep, satisfaction with social roles, pain, and physical function using the PROMISE-43 at 6 and 12 months.

- To assess baseline predictors (medical history, health behaviors, quality of life) of subjects who adhere to and complete the intervention.

- To assess the diversity of subjects who enroll and complete the intervention.

- To assess the availability and acceptability of the Curves fitness centers at 12 months.

- To explore changes in DNA methylation.

- To assess the intervention and study process via open-ended interviews with SWOG sites and Curves franchises.

- To measure changes in anthropometric measures and assess feasibility of extended follow-up at 24 and 36 months.

- To assess the safety of the Curves® fitness centers for this population by assessing self-reported changes in lymphedema and any injuries as measured at 6 and 12 months.

OUTLINE: Participants are stratified according to type of cancer (breast vs colorectal).

Participants are instructed to practice 30-45 minutes of medium-to-hard exercise 5-7 days a week at a Curves fitness center (paid by study) or outside Curves for 12 months. Participants receive written materials on physical activity guidelines for survivors and a pedometer to track their physical activity outside Curves. They also receive the Curves Fitness & Weight Management Plan and are instructed to follow a "higher carbohydrate" diet plan, which promotes a 1,500 kcal/day diet that is high in fruit and vegetables consisting of 30% protein, 45% carbohydrates, and 25% fat. In addition, participants receive the dietary guidelines for cancer survivors, which recommend eating 5 or more servings of fruit/vegetables per day, a diet high in whole grains, low in saturated fat, low in sugary foods, and low in alcohol. Participants receive 14 behavioral-counseling sessions by telephone with the goal to increase intervention adherence and participation retention. Each session lasts 40 minutes and occurs weekly on weeks 1-5 and then every 6 weeks by month 6. Participants receive monthly email newsletters with health tips and motivational messages to encourage adherence and retention to the study program. Counselors also conduct three 24-hour dietary recall assessments and 1 physical activity assessment at 6 and 12 months.

Participants complete a PROMIS-43 quality-of-life questionnaire at 6 and 12 months via internet, mail, or telephone.

Participants also undergo blood sample collection at baseline and at 6 and 12 months for fasting glucose and insulin tests, and biomarker studies. Anthropometric measurements (height, weight, waist, and hip circumference) are also collected.

After completion of study intervention, participants are followed up at 24 and 36 months.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 2017
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender Female
Age group N/A to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Participants must be women with a previous diagnosis of stage I, II, or III invasive breast cancer or colorectal cancer

- Participants must have no evidence of disease at the time of registration and no history of metastases (M0)

- Participants must have a body mass index = 25 kg/m^2 measured within 28 days of registration

- Participants must be considered sedentary (defined as < 60 minutes of moderate to vigorous physical activity per week; moderate exercise defined as exercising to the point of sweating)

- Participants must be willing to submit blood samples for biomarkers (insulin, glucose, HgbA1C, estradiol, and testosterone) and undergo DXA scans, and must be given the option to consent for specimen submission for banking and future translational medicine studies

- Participants must be willing and able to attend a Curves fitness center at least 3 times per week for 12 months

PATIENT CHARACTERISTICS:

- Participants must be post-menopausal, as defined by at least one of the following:

- At least 12 months since the last menstrual period

- Prior bilateral oophorectomy

- Previous hysterectomy with one or both ovaries left in place (or previous hysterectomy in which documentation of bilateral oophorectomy is unavailable) AND follicle-stimulating hormone (FSH) values consistent with the institutional normal values for the post-menopausal state

- If participant is under the age of 55, FSH levels must be obtained within 28 days prior to registration

- Zubrod performance status of 0

- Participants must have no abnormal changes on a regular (non-nuclear) cardiovascular exercise stress test (using a treadmill or bicycle) as measured by electrocardiogram (EKG)

- EKG must be within institutional limits of normal

- Results of previous cardiac exercise stress test may be used as long as it was done within 3 months prior to registration

- Participants must not have evidence of uncontrolled hypertension

- Participants with diabetes, pre-diabetes, and/or metabolic syndrome must have HgbA1C = 8% within the past 28 days

- Current use of diabetes medications is allowed

- No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the participant has been disease-free for > 5 years

- Participants must not be active smokers within past 90 days; active smoking is defined as any smoking, even a puff

- Participants must have regular access to the internet in order to receive monthly nutrition-program newsletter e-mails and to complete study questionnaires online

- Participants must be able to understand, speak, and read English

- Participants must have a home phone or cell phone and agree to participate in the 14 (40-minute) behavioral counseling sessions and 9 (20-30-minute) telephone interviews

- Participants must have a baseline physical exam and physician clearance (primary care provider, medical oncologist, or surgical oncologist) to participate in the weight loss and exercise prior to enrollment within 60 days of registration; copy of physician clearance document must be submitted

PRIOR CONCURRENT THERAPY:

- Participants must be 90 days to 730 days post-surgery, chemotherapy, and radiation therapy

- Current hormonal therapy is allowed among breast cancer participants

- Other concurrent anti-cancer therapies, including Herceptin, are not allowed

- Surgery is defined as any major surgical procedure (resection or reconstructive) that would preclude inclusion in the exercise program

- If the participant has had a remedial surgical procedure (e.g., revision of reconstruction) or persistent complications from her original operation, approval will be obtained from the participant's surgeon prior to enrollment

- Persistent complications may include, but are not limited to, prolonged wound healing, hernias, or ostomy prolapse

Study Design


Intervention

Behavioral:
behavioral dietary intervention
Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be < 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
exercise intervention
150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
Other:
counseling intervention
14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
Procedure:
quality-of-life assessment
PROMIS-43 - online questionnaire to assess quality of life.

Locations

Country Name City State
United States Kaiser Permanente-Deer Valley Medical Center Antioch California
United States Cancer Center of Kansas - Chanute Chanute Kansas
United States Cancer Center of Kansas - Dodge City Dodge City Kansas
United States Swedish Medical Center-Edmonds Edmonds Washington
United States Cancer Center of Kansas - Fort Scott Fort Scott Kansas
United States Kaiser Permanente, Fremont Fremont California
United States Kaiser Permanente Fresno California
United States Cancer Centers of the Carolinas - Faris Greenville South Carolina
United States Cancer Centers of the Carolinas - Grove Commons Greenville South Carolina
United States Greenville CCOP Greenville South Carolina
United States Greenville Memorial Hospital Greenville South Carolina
United States Cancer Centers of the Carolinas-Greer Medical Oncology Greer South Carolina
United States Kaiser Permanente, Hayward Hayward California
United States Kaiser Permanente Moanalua Medical Center Honolulu Hawaii
United States Cancer Center of Kansas-Independence Independence Kansas
United States University of Kansas Medical Center Kansas City Kansas
United States Cancer Center of Kansas-Kingman Kingman Kansas
United States Lawrence Memorial Hospital Lawrence Kansas
United States Cancer Center of Kansas-Liberal Liberal Kansas
United States Loyola University Medical Center Maywood Illinois
United States Kaiser Permanente-Modesto Modesto California
United States Columbia University Medical Center New York New York
United States Cancer Center of Kansas - Newton Newton Kansas
United States Kaiser Permanente-Oakland Oakland California
United States Cancer Center of Kansas - Parsons Parsons Kansas
United States Cancer Center of Kansas - Pratt Pratt Kansas
United States Kaiser Permanente-Redwood City Redwood City California
United States Kaiser Permanente-Richmond Richmond California
United States Kaiser Permanente-Roseville Roseville California
United States William Beaumont Hospital Royal Oak Michigan
United States Kaiser Permanente - Sacramento Sacramento California
United States Kaiser Permanente-South Sacramento Sacramento California
United States Cancer Center of Kansas - Salina Salina Kansas
United States Southwest Oncology Group San Antonio Texas
United States Kaiser Permanente-San Francisco San Francisco California
United States Kaiser Permanente-Santa Teresa-San Jose San Jose California
United States Kaiser Permanente-San Rafael San Rafael California
United States Kaiser Permanente Medical Center - Santa Clara Santa Clara California
United States Kaiser Permanente-Santa Rosa Santa Rosa California
United States Swedish Medical Center-First Hill Seattle Washington
United States University of Washington Medical Center Seattle Washington
United States Cancer Centers of the Carolinas - Seneca Seneca South Carolina
United States Kaiser Permanente-South San Francisco South San Francisco California
United States Cancer Centers of the Carolinas - Spartanburg Spartanburg South Carolina
United States Kaiser Permanente-Stockton Stockton California
United States William Beaumont Hospital - Troy Troy Michigan
United States Arizona Cancer Center at University Medical Center North Tucson Arizona
United States University of Arizona Health Sciences Center Tucson Arizona
United States Kaiser Permanente Medical Center-Vacaville Vacaville California
United States Kaiser Permanente-Vallejo Vallejo California
United States Kaiser Permanente-Walnut Creek Walnut Creek California
United States Cancer Center of Kansas - Wellington Wellington Kansas
United States Associates In Womens Health Wichita Kansas
United States Cancer Center of Kansas - Main Office Wichita Kansas
United States Cancer Center of Kansas-Wichita Medical Arts Tower Wichita Kansas
United States Via Christi Regional Medical Center Wichita Kansas
United States Wichita CCOP Wichita Kansas
United States Cancer Center of Kansas - Winfield Winfield Kansas

Sponsors (2)

Lead Sponsor Collaborator
Southwest Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Attendance of = 2 Curves sessions/week for a minimum of 36 of the 52 weeks of intervention 1 year from registration
Primary Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day 1 year from registration
Secondary Changes in anthropometric measures (weight, BMI, waist circumference, hip circumference) 1 year from registration
Secondary Changes in body composition (% body fat as assessed by DXA scan at 12 months only) 1 year from registration
Secondary Changes in minutes spent per week in moderate-to-vigorous intensity aerobic activity using Curves attendance records and a 7-day physical activity recall assessment 1 year from registration
Secondary Changes in dietary intake patterns based on three separate 24-hour diet recalls 1 year from registration
Secondary Changes in metabolic and hormonal biomarkers associated with breast and colorectal cancer-recurrence risk (fasting insulin, fasting glucose, hemoglobin A1C, bioavailable estradiol, free testosterone, and adiponectin) 3 years
Secondary Changes in anxiety, depression, fatigue, sleep, satisfaction with social roles, pain, and physical function as measured by the PROMIS-43 1 year from registration
Secondary DNA methylation patterns 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A